Track 01: Predictive Biomarkers and Diagnostics

In drug, a biomarker and sub-nuclear markers is the quantifiable pointer of the reality or region of some disease state. All the more overall it is anything that can be used as a marker of a particular illness state or some other physiological state of a living being Medication Symptomatic Co-Improvement. In the present time of stratified arrangement and biomarker-driven medications, the inside has moved from figures considering the customary anatomic orchestrating systems to coordinate the choice of treatment for an individual patient to a planned strategy using the inherited beautifiers of the tumour and the genotype of the patient. Genomics and different developments have, all things considered, Personalized Medicine Congress 2020 added to the unmistakable verification and the change of biomarkers, for example, Stratification biomarkers in modified pharmaceutical.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 02: Precision Pathology

The role of predictive pathology or the accurate assessment of morphology at the microscopic level. In breast cancer, this has been most useful where histologic attributes such as the classification of tubular and cribriform carcinoma dictates surgery while neoadjuvant studies suggest that patients with lobular carcinoma are not likely to benefit from chemotherapy. The next level of 'personalized pathology' at the tissue-cellular level is the use of 'protein biomarker panels' to classify the disease process and ultimately drive tumor characterization and treatment. Precision pathology will focus on the evolution of predictive pathology from a subjective, 'opinion-based' approach to a quantitative science. The individual components of the precise pathology platform including advanced image analysis, biomarker quantitation with mathematical modelling and the integration with fluid-based (i.e. blood, urine) analytics as drivers of next generation precise patient phenotyping.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 03: Drug Target Discovery and Integration

Drug Target was discovered by identifying the active ingredient from traditional remedies or by serendipitous discovery, as with penicillin. More recently, chemical libraries of synthetic small molecules, natural products or extracts were screened in intact cells or whole organisms to identify substances that had a desirable therapeutic effect in a process known as classical pharmacology. After sequencing of the human genome allowed rapid cloning and synthesis of large quantities of purified proteins, it has become common practice to use high throughput screening of large compounds libraries against isolated biological targets which are hypothesized to be disease-modifying in a process known as reverse pharmacology. Hits from these screens are then tested in cells and then in animals for efficacy. Modern drug discovery and Integration involves the identification of screening hits, medicinal chemistry and optimization of those hits to increase the affinity, selectivity (to reduce the potential of side effects), efficacy/potency, metabolic stability (to increase the half-life), and oral bioavailability. Once a compound that fulfills all of these requirements has been identified, the process of drug development can continue, and, if successful, clinical trials. One or more of these steps may, but not necessarily, involve computer-aided drug design.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 04: Precision Medicine in Cancer Diagnosis and Treatment

The goal of surgery is to remove the cancer or as much of the cancer as possible. Chemotherapy uses drugs to kill cancer cells. Radiation therapy uses high-powered energy beams, such as X-rays, to kill cancer cells. Radiation treatment can come from a machine outside your body or it can be placed inside your body (brachytherapy). Bone marrow transplant is also known as a stem cell transplant. Your bone marrow is the material inside your bones that makes blood cells. A bone marrow transplant can use your own cells or cells from a donor. A bone marrow transplant allows your doctor to use higher doses of chemotherapy to treat your cancer. It may also be used to replace diseased bone marrow. Immunotherapy, also known as biological therapy, uses your body's immune system to fight cancer. Cancer can survive unchecked in your body because your immune system doesn't recognize it as an intruder. Immunotherapy can help your immune system "see" the cancer and attack it. Some types of cancer are fuelled by your body's hormones. Examples include breast cancer and prostate cancer. Removing those hormones from the body or blocking their effects may cause the cancer cells to stop growing. Targeted drug treatment focuses on specific abnormalities within cancer cells that allow them to survive. Clinical trials are studies to investigate new ways of treating cancer. Thousands of cancer clinical trials are underway.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 05: Preventive Medicine & Public Health Care

Preventive Medicine is sharpened by all specialists to keep their patients sound. It is also an extraordinary therapeutic distinguishing strength saw by the American Board of Medical Specialties (ABMS). Preventive Medicine focuses on the prosperity of individuals, gatherings, and portrayed peoples. It is similarly used for the treatment for strength, visual hindrance. The Epidemiology Division applies inquire about systems to illustrations and explanations behind prosperity and affliction in the people and to make a translation of this learning into ventures proposed to turn away disease. The division has a long history of consideration in NIH-bolstered multi-site, longitudinal accomplice studies, and its staff deal with various pro began, NIH-upheld investigation endeavours and trials. Open trust in antibodies is a key to the accomplishment of immunization ventures worldwide in the time of preventive solution. The focus of Preventive Medicine and Public Health is health of individuals, communities, and defined populations. To, maintain health and protect, promote and to prevent disease, death and disability. The result of Public health surveillance is the identification and prioritization of public health issues the world is facing today, including HIV/AIDS, antibiotic resistance, diabetes, zoonotic diseases, and waterborne diseases. Preventive Medicine and Public health incorporates the interdisciplinary approaches of epidemiology, biostatistics and health services.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 06: Precision Medicine: Oncology and Cardiovascular

Precision Medicine in Oncology is doled out to illuminating, instructing, and encouraging the trading of clinically pertinent data with respect to the disclosure and utilization of new Drug regimens, Molecular biomarkers, Cancer genomics, Molecular growth and Diagnostics in strong tumors and hematologic malignancies, and in addition their effect on oncology watch over patients. Over late decades Cancer investigate has found an incredible and personalized medication to tumor research and treatment. The goal of the Personalized Medicine in cardiac research is to stimulate understanding of promising new essential examination disclosures for the treatment of heart disillusionment and arrhythmias through especially formed clinical trials that display suitability and security. Vascular Medicine encompasses an extensive variety of various sickness states. As the field of vascular Medicine builds up, the degree of ailments being managed changes. Cardiovascular revamping suggests the changes in estimate, shape, structure and physiology of the heart after harm to the myocardium. The mischief is regularly a direct result of extraordinary myocardial dead tissue. To depict the development in lipoprotein translation by hypothyroidism, adipocytes were prepared from control and hypothyroid rats. While LPL mix was higher in hypothyroid adipocytes, with no modification in mRNA levels, there was no extension in hormone-delicate lipase (HSL) mix.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 07: Precision Medicine: Data Analysis and Big Data Management

Genomic medicine attempts to build individualized strategies for diagnostic or therapeutic decision-making by utilizing patients’ genomic information. Big Data analytics uncovers hidden patterns, unknown correlations, and other insights through examining large-scale various data sets. While integration and manipulation of diverse genomic data and comprehensive electronic health records (EHRs) on a Big Data infrastructure exhibit challenges, they also provide a feasible opportunity to develop an efficient and effective approach to identify clinically actionable genetic variants for individualized diagnosis and therapy. In this paper, we review the challenges of manipulating large-scale next-generation sequencing (NGS) data and diverse clinical data derived from the EHRs for genomic medicine. We introduce possible solutions for different challenges in manipulating, managing, and analyzing genomic and clinical data to implement genomic medicine.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 08: Precision Immunotherapy

Immunotherapy is a type of treatment that helps the body’s immune system fight cancer. Several kinds of immunotherapy, including immune checkpoint inhibitors, adoptive cell transfer, and therapeutic vaccines are either commercially available or in clinical development. To date, six immune checkpoint inhibitors have been approved by FDA for the treatment of eight types of cancer. One of the inhibitors has also been approved to treat any solid tumor that has a specific genetic feature. This was the first FDA approval of its kind and a major advance for precision cancer medicine, in which the molecular characteristics of a tumor are used to identify effective therapies.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 09: Advances in Precision Diagnostics

Precision medicine aims to tailor treatments based on individual characteristics, including differences in genetics, environment, and lifestyle. It has the potential to transform the delivery of care for a variety of diseases and we are already seeing the benefits of this approach in oncology. To highlight the importance of precision medicine and the key role of diagnostics in ensuring the success of President Obama's Precision Medicine Initiative, the AACR and AdvaMedDx held a congressional briefing featuring some of the top minds across the medical research spectrum, from government agencies, academia, industry, and patient advocacy.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 10: Proteomics and Genomics in Personalized Medicine

The proteome is the entire set of proteins it is expressed by genome, cell, tissue, or organism at a certain time. More specifically, it is a combined of proteins and genomes. Proteomics is the study of the proteome. A cellular proteome is the collection of proteins present in a particular cell type and it exposure to hormone stimulation. It can also be useful to consider an organisms complete proteome, which can be conceptualized as the complete set of proteins from all of the various cellular proteomes. Proteome used to refer to the collection of proteins in certain sub-cellular biological systems.

Relevant Societies and Associations:International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 11: Personalized Drug Therapy in Diabetics

The definition of personalized medicine for diabetes (PMFD) is the use of information about the genetic makeup of a person with diabetes to tailor strategies for preventing, detecting, treating, or monitoring their diabetes. The practice of PMFD involves four processes. First is the identification of genes and biomarkers for diabetes as well as for obesity, which is the greatest risk factor for type 2 diabetes. Second, after these predictors of diabetes are identified, is allocation of resources to prevent or detect the diabetes and/or obesity phenotype in high-risk individuals, whose risk is based on their genotype. Third is selection of individualized therapies for affected individuals. The selection process involves deciding which drug to prescribe, what dose of drug to use, and which diet to prescribe. The selection process also accounts for which drug is least likely to cause side effects or toxicity. Fourth is measurement of circulating biomarkers of diabetes to monitor the response to prevention or therapy.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 12: Personalised medicine for CNS diseases

A neurological issue is any tumor of the body sensory system. Auxiliary, biochemical or electrical variations from the norm of mind, spinal string or different nerves can bring about a scope of side effects. The indications incorporate loss of motion, muscle shortcoming, loss of sensation, seizures perplexity torment and changed levels of consciousness. They might be surveyed by neurological examination, considered and treated inside the specialities of neurology and clinical neuropsychology.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 13: Treatment of Genetic Disorders

Gene therapy is hoped to cure or improve treatment of genetic disorders by replacing the mutated or malfunctioned gene, manipulating or turning off the gene causing the disease or stimulate other bodily functions to fight the disease. The most common method is replacement of a malfunctioned or sometimes a missed gene with a healthy one. However, gene therapy poses a risk of potentially serious complications, in the first place due to the method that is used to insert the “new” genes – the use of viruses. These have the ability to identify certain cells as well as to transmit the genetic material into the cells containing malfunctioned or missed gene. For that reason modified viruses are used as vectors or carriers of the healthy genes. This method of insertion of healthy genes may not seem problematic at a first glance but it can cause cause potentially serious complications as already mentioned earlier.

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Track 14: Stem Cells and Cell therapy

Personalized Medicine can be used to discover around a man's genetic beauty care products and to unravel the study of their tumor. Using this information, experts need to perceive reckoning, screening, and treatment procedures that may be more fruitful and cause less indication than would be ordinary with standard drugs. By performing more innate tests and examination, authorities may adjust treatment to each patient's needs. Making a tweaked harm screening and treatment game plan consolidates: Determining the chances that a man will make development and choosing screening methods to cut down the threat, Matching patients with meds that will presumably be convincing and cause less responses, Predicting the risk of rehash (return of Cancer).

Relevant Societies and Associations:

International Society of Personalized Medicine; Hungarian Society of Personalized Medicine; International Society of Personalized Medicine (ISPM); Italian Society of Personalized Medicine; Turkish P4 Medicine Association (PDER4); Spanish Society of Pharmacogenetics and Pharmacogenomics; British Network Pharmacogenomics and Personalized Medicine; Korean Network Pharmacogenomics and Personalised Medicine; Serbian Society of Pharmacogenomics and Theranostics; Israeli  Network Pharmacogenomics and Personalized Medicine; The Swiss group of Pharmacogenomics and Personalized Medicine; German Society on Pharmacogenomics and Personalized medicine; Russian Network Pharmacogenomics and Personalized Medicine; Iranian Network Pharmacogenomics and Personalized Medicine; Chinese Network Pharmacogenomics and Personalized Medicine; Canadian Network Pharmacogenomics and Personalised Medicine; Egyptian Network Pharmacogenomics and Personalised Medicine; European Society of Pharmacogenomics and Personalised Therapy (ESPT).

Summary of Personalized Medicine Congress 2020:-

12th World Congress on Precision and Personalized Medicine contribute the opportunities to determine advance techniques used in Diagnostics labs, Genetics, Biology labs and which basically deals with the latest research and developments in the sphere of genetics and molecular biology. This Conference will provide a perfect platform to all the International mix of leading Research Scholars, and Scientists achieved eminence in their field of study, research academicians from the universities and research institutions, industrial research professionals and business associates along with PhD Students to come and inform all the attendees about the latest scientific advancements on the respective sphere.

Scope and importance:

12th World Congress on Precision and Personalized Medicine is a perfect platform for Expanding the innovative techniques and novel research trends in clinical genetics. Clinical research is a versatile conference that offers expert diagnosis, treatment all types of disorders in genetics and Drug therapies, Biological therapies. With the Annual meeting on Geneticist’s, Cytopathologists, Pathologist, Clinical research, case reports we will expect the expert gathering from Universe so that novel idea or novel research will come with a discussion at the conference and that will be fruitful to children adversity from different types of diseases. This International Personalized Medicine Conference additionally supports the dynamic cooperation of youthful understudy analysts as we are facilitating Poster Award Competition and Young research Forum at the meeting setting.

Market research:

The global personalized medicine in the market was valued at USD 1,007.88 billion in 2018 and is expected to reach USD 2,452.50 billion in 2022, growing at a CAGR of 11.8% over the forecast period. Key drivers of the market include growing development of next-generation sequencing, whole genome technology, companion diagnostics and the growing number of retail clinics. Growing healthcare expenditure levels triggering the need for an effective diagnostic procedure for cancer, the growing prevalence of cancer and increasing usage of combination biomarkers for diagnostics are few factors expected to boost market growth. Increasing adoption of next-generation sequencing for genetic mapping of patients by clinicians and medical practitioners worldwide and growing support for personalized medicine by reimbursement and regulatory landscape are also factors expected to drive demand through to 2022. Market growth is also expected to rise through the novel introduction of drugs with associated and companion diagnostics, and growing usage of highly sensitive, accurate genetic diagnostic techniques for disease testing and risk assessment. Anticipated increase advanced DNA diagnostic usage combined with the reduction in implementation costs for whole genome sequencing is expected to considerably increase penetration rates.